GGGege Gui

Gege Gui

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gege Gui has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    Single-cell spatial transcriptomics reveals immunotherapy-driven bone marrow niche remodeling in AML

    by Gege Gui, Molly A. Bingham, Julius R. Herzog, Abigail Wong-Rolle, Laura W. Dillon, Meghali Goswami, Eddie Martin, Jason Reeves, Sean Kim, Arya Bahrami, et al.

    Given the graft-versus-leukemia effect observed with allogeneic hematopoietic stem cell transplantation in refractory or relapsed acute myeloid leukemia (AML), immunotherapies have been explored in nontransplant settings. We applied a multiomic approach to examine bone marrow interactions in patients with AML treated with pembrolizumab and decitabine. Using extensively trained nuclear and membrane segmentation models, we achieved precise transcript assignment and deep learning–based image analysis. To address read-depth limitations, we integrated single-cell RNA sequencing with single-cell spatial transcriptomics from the same sample. Quantifying cell-cell distances at the edge level enabled more accurate tumor microenvironment analysis, revealing global and local immune cell enrichment near leukemia cells postpembrolizumab treatment, potentially linked to clinical response. Furthermore, ligand-receptor analysis indicated potential alterations in specific signaling pathways between leukemia and immune cells following immunotherapy treatment. These findings provide insights into immune interactions in AML and may inform therapeutic strategies.


  • Open Access

    Pre-MEASURE: FLT3 -ITD and mutated NPM1 measurable residual disease before allogeneic transplant in adults with AML in first remission

    by Laura W Dillon, Gege Gui, Niveditha Ravindra, Zoë Wong, Georgia Andrew, Devdeep Mukherjee, Scott L. Zeger, Firas El Chaer, Stephen Spellman, Alan Howard, et al.

    Background: Prevention of relapse for adults with Acute Myeloid Leukemia (AML) in first remission (CR1) is the most common indication for allogeneic hematopoietic cell transplantation (alloHCT). Measurable residual disease (MRD) detection has been associated with higher relapse rates, but testing is not standardized. Establishment of validated AML MRD criteria would allow harmonization across centers facilitating clinical trials and generalizable practice guidelines. Methods: Patients aged 18 or older who underwent first alloHCT for FLT3, NPM1, IDH1, IDH2 and/or KIT mutated AML in CR1 were eligible for this multicenter study. Residual mutations detected in remission using ultra-deep error-corrected next-generation DNA-sequencing (NGS-MRD) associated with increased relapse risk were validated in a second independent cohort. The impact of baseline characteristics on NGS-MRD results was evaluated. Results: Pre-conditioning CR1 blood samples from 1075 patients were tested. Detection of residual NPM1 and/or FLT3 -ITD mutations before alloHCT was associated with worse outcomes after transplantation in both discovery (patients transplanted 2013-2017) and validation (patients transplanted 2018-2019) cohorts. In multivariate Cox regression analysis detection of residual NPM1 m (relapse; HR: 4.9, 3.5-7.0, PFLT3 -ITD (relapse: HR: 4.2, 3.1-5.7, PNPM1 and/or FLT3 -ITD mutations in the blood of patients undergoing alloHCT for AML in CR1 is associated with increased relapse and worse survival. In those undergoing reduced intensity conditioning, melphalan may reduce the risk associated with testing NGS-MRD positive prior to transplantation.